新型冠狀病毒

CureVac sues BioNTech over mRNA patents

Pharma group seeks compensation from Covid vaccine maker over alleged IP infringements

CureVac is suing fellow German pharmaceutical company BioNTech, claiming that the Covid-19 vaccine maker infringed vital patents relating to messenger RNA technology.

The Tübingen-based group has filed a lawsuit in a German court seeking “fair compensation” for alleged infringements of its intellectual property rights in the development of the Covid shot made by BioNTech and US drugmaker Pfizer.

But it said it was not planning any action that would affect the production, sale or distribution of the vaccine.

您已閱讀35%(513字),剩餘65%(968字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×